{"id":"https://openalex.org/W7168154455","doi":"https://doi.org/10.7326/annals-25-00860","title":"Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy","display_name":"Glucagon-like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy","publication_year":2026,"publication_date":"2026-07-13","ids":{"openalex":"https://openalex.org/W7168154455","doi":"https://doi.org/10.7326/annals-25-00860","pmid":"https://pubmed.ncbi.nlm.nih.gov/42441967"},"language":"en","primary_location":{"id":"doi:10.7326/annals-25-00860","doi":"https://doi.org/10.7326/annals-25-00860","is_oa":false,"landing_page_url":"https://doi.org/10.7326/annals-25-00860","pdf_url":null,"source":{"id":"https://openalex.org/S119722071","display_name":"Annals of Internal Medicine","issn_l":"0003-4819","issn":["0003-4819","1539-3704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316812","host_organization_name":"American College of Physicians","host_organization_lineage":["https://openalex.org/P4310316812"],"host_organization_lineage_names":["American College of Physicians"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Internal Medicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071149526","display_name":"Kamika R. Reynolds","orcid":"https://orcid.org/0000-0002-7460-6756","observed_orcids":["https://orcid.org/0000-0002-7460-6756"]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kamika R. Reynolds","raw_affiliation_strings":["Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (K.R.R., K.M.O., C.V.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (K.R.R., K.M.O., C.V.D.)","institution_ids":["https://openalex.org/I102322142"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5140534257","display_name":"Kimberly M. O\u2019Malley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberly M. O\u2019Malley","raw_affiliation_strings":["Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (K.R.R., K.M.O., C.V.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (K.R.R., K.M.O., C.V.D.)","institution_ids":["https://openalex.org/I102322142"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102729009","display_name":"Jason A. Roy","orcid":"https://orcid.org/0000-0003-4237-0504","observed_orcids":["https://orcid.org/0000-0003-4237-0504"]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason A. Roy","raw_affiliation_strings":["Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, New Jersey (J.A.R.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, New Jersey (J.A.R.)","institution_ids":["https://openalex.org/I102322142"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101652561","display_name":"Chintan V. Dave","orcid":"https://orcid.org/0000-0002-7160-9345","observed_orcids":["https://orcid.org/0000-0002-7160-9345"]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chintan V. Dave","raw_affiliation_strings":["Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (K.R.R., K.M.O., C.V.D.)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Center for Health Outcomes, Policy, and Economics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (K.R.R., K.M.O., C.V.D.)","institution_ids":["https://openalex.org/I102322142"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I102322142"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.48317041,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"179","issue":"9","first_page":"1244","last_page":"1253"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.00430000014603138,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9860000014305115},{"id":"https://openalex.org/keywords/non-arteritic-anterior-ischemic-optic-neuropathy","display_name":"nonarteritic anterior ischemic optic neuropathy","score":0.9340000152587891},{"id":"https://openalex.org/keywords/ischemic-optic-neuropathy","display_name":"ischemic optic neuropathy","score":0.9869999885559082},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9330000281333923},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.8769999742507935},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.8510000109672546},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.652999997138977},{"id":"https://openalex.org/keywords/risk-difference","display_name":"risk difference","score":0.45899999141693115},{"id":"https://openalex.org/keywords/number-needed-to-harm","display_name":"number needed to harm","score":0.6819999814033508},{"id":"https://openalex.org/keywords/cardiovascular-disease","display_name":"cardiovascular disease","score":0.3310000002384186},{"id":"https://openalex.org/keywords/ophthalmic-conditions","display_name":"ophthalmic conditions","score":0.6159999966621399},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.550000011920929},{"id":"https://openalex.org/keywords/age-differences","display_name":"age differences","score":0.8479999899864197},{"id":"https://openalex.org/keywords/commercial-claims","display_name":"commercial claims","score":0.39399999380111694}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9488000273704529},{"id":"https://openalex.org/C2780498249","wikidata":"https://www.wikidata.org/wiki/Q6079225","display_name":"Ischemic optic neuropathy","level":3,"score":0.4846000075340271},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.46160000562667847},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4311999976634979},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4239000082015991},{"id":"https://openalex.org/C2780837183","wikidata":"https://www.wikidata.org/wiki/Q186029","display_name":"Optic nerve","level":2,"score":0.3986000120639801},{"id":"https://openalex.org/C2778233873","wikidata":"https://www.wikidata.org/wiki/Q2879095","display_name":"Optic neuropathy","level":3,"score":0.3628000020980835},{"id":"https://openalex.org/C2779901536","wikidata":"https://www.wikidata.org/wiki/Q945238","display_name":"Peripheral neuropathy","level":3,"score":0.3425000011920929},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.3384000062942505},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3102000057697296},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.30820000171661377},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3061999976634979},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3059000074863434},{"id":"https://openalex.org/C541997718","wikidata":"https://www.wikidata.org/wiki/Q188151","display_name":"Ischemia","level":2,"score":0.301800012588501},{"id":"https://openalex.org/C2776763380","wikidata":"https://www.wikidata.org/wiki/Q362719","display_name":"Anterior ischemic optic neuropathy","level":3,"score":0.3000999987125397},{"id":"https://openalex.org/C3020199598","wikidata":"https://www.wikidata.org/wiki/Q12202","display_name":"Ischemic stroke","level":3,"score":0.2994000017642975},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.2578999996185303},{"id":"https://openalex.org/C2780645631","wikidata":"https://www.wikidata.org/wiki/Q671554","display_name":"Stroke (engine)","level":2,"score":0.2574000060558319},{"id":"https://openalex.org/C2780942790","wikidata":"https://www.wikidata.org/wiki/Q372016","display_name":"Pathogenesis","level":2,"score":0.2565999925136566},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.25589999556541443},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.25380000472068787}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018917","descriptor_name":"Optic Neuropathy, Ischemic","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D018917","descriptor_name":"Optic Neuropathy, Ischemic","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.7326/annals-25-00860","doi":"https://doi.org/10.7326/annals-25-00860","is_oa":false,"landing_page_url":"https://doi.org/10.7326/annals-25-00860","pdf_url":null,"source":{"id":"https://openalex.org/S119722071","display_name":"Annals of Internal Medicine","issn_l":"0003-4819","issn":["0003-4819","1539-3704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316812","host_organization_name":"American College of Physicians","host_organization_lineage":["https://openalex.org/P4310316812"],"host_organization_lineage_names":["American College of Physicians"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Internal Medicine","raw_type":"journal-article"},{"id":"pmid:42441967","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42441967","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of internal medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G9000863303","display_name":"(R01) Strengthening the Evidence-Base to Support Medication Prescribing in Older Adults with Chronic Kidney Disease","funder_award_id":"R01DK139163","funder_id":"https://openalex.org/F4320337357","funder_display_name":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"id":"https://openalex.org/G9000868480","display_name":"Evaluating the role of multimorbidity in modulation medication effects in older adults","funder_award_id":"R01HL163163","funder_id":"https://openalex.org/F4320337338","funder_display_name":"National Heart, Lung, and Blood Institute"}],"funders":[{"id":"https://openalex.org/F4320337338","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26"},{"id":"https://openalex.org/F4320337357","display_name":"National Institute of Diabetes and Digestive and Kidney Diseases","ror":"https://ror.org/00adh9b73"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W2005800454","https://openalex.org/W2036193982","https://openalex.org/W2049491523","https://openalex.org/W2087018232","https://openalex.org/W2089486126","https://openalex.org/W2094325655","https://openalex.org/W2434859067","https://openalex.org/W2521391825","https://openalex.org/W2773101798","https://openalex.org/W2796984446","https://openalex.org/W2802890213","https://openalex.org/W3005269555","https://openalex.org/W4285742372","https://openalex.org/W4292371522","https://openalex.org/W4387118591","https://openalex.org/W4388523165","https://openalex.org/W4389571899","https://openalex.org/W4391294421","https://openalex.org/W4396664258","https://openalex.org/W4400280960","https://openalex.org/W4400281029","https://openalex.org/W4400874445","https://openalex.org/W4401191418","https://openalex.org/W4403128717","https://openalex.org/W4403941065","https://openalex.org/W4403999311","https://openalex.org/W4405516842","https://openalex.org/W4406733030","https://openalex.org/W4408461496","https://openalex.org/W4408584919","https://openalex.org/W4412943903"],"related_works":["https://openalex.org/W7168147240","https://openalex.org/W7129332889","https://openalex.org/W7207860402","https://openalex.org/W7128598885","https://openalex.org/W7118504362","https://openalex.org/W4415300883","https://openalex.org/W7214907749","https://openalex.org/W7164149498","https://openalex.org/W7159633754","https://openalex.org/W7213969922"],"abstract_inverted_index":{"BACKGROUND:":[0],"There":[1],"are":[2],"few":[3],"data":[4,276],"evaluating":[5],"the":[6,36,191,300],"association":[7,302],"between":[8],"glucagon-like":[9],"peptide-1":[10],"receptor":[11],"agonists":[12],"(GLP-1RAs)":[13],"and":[14,45,116,120,156,182,202,217,229,233,248,261,286,321],"nonarteritic":[15],"anterior":[16],"ischemic":[17,26],"optic":[18,27],"neuropathy":[19,28],"(NAION),":[20],"which":[21],"constitutes":[22],"approximately":[23],"75%":[24],"of":[25,38,57,113,190,222,307,319,340],"(ION)":[29],"cases":[30],"in":[31,196,206,240,259],"adults.":[32],"OBJECTIVE:":[33],"To":[34],"estimate":[35],"effect":[37],"GLP-1RAs":[39,308],"versus":[40,138,146,158,166,231],"sodium-glucose":[41],"cotransporter-2":[42],"inhibitors":[43,48],"(SGLT2is)":[44],"dipeptidyl":[46],"peptidase-4":[47],"(DPP4is)":[49],"on":[50,277],"risk":[51,121,133,314,325],"for":[52,101,105,134,271,315],"ION.":[53],"DESIGN:":[54],"Observational":[55],"emulation":[56],"a":[58,84,89,99],"target":[59],"trial.":[60],"SETTING:":[61],"Large":[62],"U.S.-based":[63],"commercial":[64],"claims":[65],"database":[66],"(January":[67],"2017":[68],"to":[69,76,154,173,178,293],"December":[70],"2022).":[71],"PARTICIPANTS:":[72],"Patients":[73],"aged":[74,243],"18":[75],"65":[77],"years":[78,201,245],"with":[79,220,250,256,311],"type":[80,287],"2":[81,223,288],"diabetes":[82,226,289],"initiating":[83],"GLP-1RA,":[85],"an":[86],"SGLT2i,":[87],"or":[88,224,246,253],"DPP4i.":[90],"MEASUREMENTS:":[91],"The":[92,131],"primary":[93],"outcome":[94],"was":[95,136,309],"incident":[96],"ION":[97,135,193,316],"as":[98,282],"proxy":[100],"NAION.":[102],"Analyses":[103],"adjusted":[104],"more":[106,225],"than":[107,199,264,317],"80":[108],"covariates":[109],"using":[110],"inverse":[111],"probability":[112],"treatment":[114],"weights,":[115],"18-month":[117,132,313],"cumulative":[118],"incidence":[119],"differences":[122,209,237,258,330],"(RDs)":[123],"per":[124,140,160],"10":[125,141,161],"000":[126,142,162],"patients":[127,242],"were":[128,180,210,238,273],"estimated.":[129],"RESULTS:":[130],"8.5":[137],"5.5":[139],"among":[143,163,212],"GLP-1RA":[144,164,186],"users":[145,148,165,168,215,221],"SGLT2i":[147],"(RD,":[149,169],"3.0":[150],"[95%":[151],"CI,":[152],"0.4":[153],"5.7])":[155],"7.8":[157],"4.2":[159],"DPP4i":[167],"3.6":[170],"[CI,":[171],"1.1":[172],"6.1]).":[174],"Corresponding":[175],"numbers":[176],"needed":[177],"harm":[179],"3333":[181],"2778,":[183],"respectively.":[184,235],"Among":[185],"users,":[187],"69":[188],"(85.2%)":[189],"81":[192],"events":[194],"occurred":[195,205],"persons":[197],"older":[198],"50":[200,244,265],"57":[203],"(70.3%)":[204],"men.":[207],"Risk":[208,236],"attenuated":[211],"metformin":[213],"monotherapy":[214],"(2.0":[216],"4.1)":[218],"compared":[219],"medications":[227],"(5.7":[228],"4.0)":[230],"SGLT2is":[232,320],"DPP4is,":[234,322],"higher":[239,312],"men,":[241],"older,":[247],"those":[249,262],"cardiovascular":[251],"disease":[252],"ophthalmic":[254],"conditions,":[255],"minimal":[257],"women":[260],"younger":[263],"years.":[266],"LIMITATIONS:":[267],"Diagnostic":[268],"codes":[269],"specifically":[270],"NAION":[272],"lacking.":[274],"Missing":[275],"key":[278],"clinical":[279],"factors":[280],"(such":[281],"body":[283],"mass":[284],"index":[285],"duration)":[290],"may":[291,331],"contribute":[292],"residual":[294,333],"confounding,":[295],"leaving":[296],"uncertainty":[297],"about":[298],"whether":[299],"observed":[301],"is":[303],"causal.":[304],"CONCLUSION:":[305],"Use":[306],"associated":[310],"use":[318],"although":[323],"absolute":[324],"remained":[326],"very":[327],"low.":[328],"Observed":[329],"reflect":[332],"confounding.":[334],"PRIMARY":[335],"FUNDING":[336],"SOURCE:":[337],"National":[338],"Institutes":[339],"Health.":[341]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-07-14T00:00:00"}